Vertex’s drug for almost all cystic fibrosis patients approved five months early


Boston-based Vertex Pharmaceuticals Inc. has achieved one of the biggest feats to date for cystic fibrosis patients — a treatment that could benefit 90 percent of patients with the rare lung disease.

The FDA approved a combination of three drugs Monday called Trikafta, which targets a mutation in the F508del gene. That genetic error is found in approximately 90 percent of patients with the rare lung disease.

"If you think about it, we went from being able to treat no patients to being able to…

Previous Billion-dollar Chicago private equity firm opens Nashville office
Next Looking for a fairer fight with your HOA? In Colorado, help may be on the way